Rheumatology Advance Access originally published online on September 7, 2004
Rheumatology 2005 44(1):24-31; doi:10.1093/rheumatology/keh398
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology Vol. 44 No. 1 © British Society for Rheumatology 2004; all rights reserved
PAPER |
The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis
1 Division of Medicine, Imperial College London, London, 2 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, 3 Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford and 4 University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK.
Correspondence to: N. Dalbeth, Department of Immunology, Imperial College London, Commonwealth Building, Hammersmith Campus, Du Cane Rd, London W12 0NN, UK. E-mail: n.dalbeth{at}ic.ac.uk
Objectives. In addition to its vasoactive effects, angiotensin II has proinflammatory properties. Angiotensin-converting enzyme (ACE) inhibitors reduce the production of angiotensin II and could therefore act as anti-inflammatory agents. Here we investigated the capacity of the ACE inhibitor quinapril to modulate inflammatory arthritis.
Methods. We studied the effect of quinapril on disease activity in mice with collagen-induced arthritis (CIA). Mice received oral quinapril (10 mg/kg/day) at the time of arthritis induction (prophylaxis protocol) or at the onset of mild arthritis (therapy protocol). Concentrations of immunoglobulin G (IgG) subtypes specific for bovine Type II collagen and TNF-
were measured by enzyme-linked immunoassay.
Results. Quinapril significantly diminished the activity of CIA when given as prophylaxis or therapy (prophylaxis protocol, P<0.001; therapy protocol P = 0.002). Antigen-specific IgG2a antibodies were reduced by 52% (P = 0.02) in the quinapril prophylaxis protocol. Suppression of arthritis by quinapril was associated with reduced articular expression of TNF- by 68% (P = 0.01) in the prophylaxis protocol and 27% (P = 0.06) in the therapy protocol. Quinapril therapy also inhibited expression of splenocyte TNF- production following lipopolysaccharide (LPS) in vitro stimulation by 59% (P = 0.02). In parallel human in vitro experiments, ACE inhibition suppressed LPS-stimulated production of TNF- by monocytes. In order to confirm that the action of quinapril occurred predominantly through suppression of angiotensin II, parallel experiments with the angiotensin receptor antagonist candesartan cilexetil demonstrated that this agent also inhibited disease activity in CIA.
Conclusions. These data suggest that angiotensin II is a mediator of chronic inflammation and that ACE inhibition may have therapeutic effects in human inflammatory arthritis.
KEY WORDS: Angiotensin II, Inflammation, Monocytes/Macrophages, Rheumatoid Arthritis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Pattacini, B. Casali, L. Boiardi, N. Pipitone, L. Albertazzi, and C. Salvarani Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-{kappa}B pathway Rheumatology, August 1, 2007; 46(8): 1252 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|